E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic or unresectable papillary thyroid cancer positive for BRAFV600 mutation and resistant to radioactive iodine therapy |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10033701 |
E.1.2 | Term | Papillary thyroid cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate best overall response rate (BORR) (complete + partial response) in Cohort 1 (TKI-naïve patients).
− BORR will be based on investigator assessment, based on the findings on computed tomography (CT) or magnetic resonance imaging, using RECIST 1.1 |
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate clinical benefit rate (CBR) in TKI-naïve patients
2. To further assess efficacy of vemurafenib using the following secondary variables: duration of response, progression free survival (PFS), and overall survival (OS) in TKI-naïve patients
3. To evaluate the efficacy (BORR, CB, duration of response, PFS, and OS) in TKI-exposed patients
4. To evaluate the tolerability and safety profile of vemurafenib using the NCI CTCAE (version 4.0) in both TK-naïve and TKI-treated patients
5. To characterize the pharmacokinetic (PK) profile of vemurafenib in patients with thyroid cancer |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Adult patients. >/= 18 years of age
- Metastatic or unresectable papillary thyroid cancer for which standard curative or palliative measures do not exist or are no longer effective
- Positive for BRAF V600 mutation (Roche Cobas 4800 BRAF V600 Mutation Test)
- Radioactive Iodine resistant disease
- Prior therapy excluding (Cohort 1) or including (Cohort 2) tyrosine kinase inhibitor with activity against VEGFR2
- Clinically relevant disease progression according to RECIST criteria within the prior 14 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate hematological, renal and liver function |
|
E.4 | Principal exclusion criteria |
- Histological diagnosis other than papillary thyroid carcinoma (PTC), including squamous cell variants of PTC or PTC with areas of squamous metaplasia
- Active or untreated CNS metastases
- History of or known carcinomatous meningitis
- Anticipated or ongoing administration of any anti-cancer therapies other than those administered in the study
- Active squamous cell skin cancer that has not been excised or adequately healed post excision
- Previous treatment with any agent that specifically and selectively targets the MEK or BRAF pathway
- Prior radiotherapy to the only measurable lesion
- Clinically relevant cardio-vascular disease or event within the prior 6 months |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Best overall response rate (BORR) in tyrosine kinase inhibitor-naïve patients (Cohort 1), assessed by the investigator according to RECIST criteria |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Clinical benefit rate (objective response rate + stable disease) in tyrosine kinase inhibitor-naïve patients
2. Duration of response in tyrosine kinase inhibitor-naïve patients
3. Progression-free survival in tyrosine kinase inhibitor-naïve patients
4. Overall survival in tyrosine kinase inhibitor-naïve patients
5. Best overall response rate in tyrosine kinase inhibitor-exposed patients (Cohort 2)
6. Clinical benefit rate in tyrosine kinase inhibitor-exposed patients
7. Duration of response in tyrosine kinase inhibitor-exposed patients
8. Progression-free survival in tyrosine kinase inhibitor-exposed patients
9. Overall survival in tyrosine kinase inhibitor-exposed patients
10. Safety: Incidence of adverse events
11. Pharmacokinetics (Tmax, Cmax, Cmin, AUC) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Time Frame: 18 months
2. Time Frame: 4.5 years
3. Time Frame: 4.5 years
4. Time Frame: 4.5 years
5. Time Frame: 18 months
6. Time Frame: 18 months
7. Time Frame: 4.5 years
8. Time Frame: 4.5 years
9. Time Frame:4.5 years
10. Time Frame:4.5 years
11. Time Frame: 4.5 years |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Samples for BRAF V600 testing, exploratory biomarkers, Roche Clinical Repository, tolerability |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 8 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Italy |
Netherlands |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will end when all patients have completed at least 6 months of follow up after discontinuation of study drug. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 0 |